Although gene alteration in KEAP1 or NFE2L2, encoding NRF2, are found in approximately 4 % of all cancer samples according to the cBioportal database, tumors harboring KEAP1 or NRF2 mutations are particularly higher in lung cancer (15 % or 9 %, respectively). This evidence concerns the gene NFE2L2 and lung carcinoma.